On March 5, 2026, Bruno Lina, President of IDCluster, and Pierre-Edouard Fournier, Director of IHU Méditerranée Infection, signed a strategic partnership agreement aimed at promoting the development of joint projects and advancing research in the fields in the fields of emerging infectious diseases (EID) and antimicrobial resistance (AMR).

Driven by a shared desire to strengthen synergies between academic research, innovation, and industrial transfer, using a One Health approach, this partnership focuses on two main areas:

1 – Sharing expertise to accelerate R&D projects

The aim is to identify promising research and development projects from the IHU Méditerranée Infection and its ecosystem of academic, hospital, and economic players that could benefit from IDCluster’s acceleration support.

This collaboration will be based in particular on the MediCA²C (Mediterranean Center of Antimicrobial Agents and Chemotherapy) project, an open and independent international network bringing together Euro-Mediterranean universities and hospitals, which aims to strengthen research, care, education, and infrastructure around antimicrobial agents and pollutants in the Mediterranean basin.

2 – Strategic cooperation around the ID360 platform

The partnership also provides for active contribution by the IHU to the future ID360 platform, supported by IDCluster and ANRS MIE. Designed as a scientific and economic intelligence platform, ID360 aims to become a benchmark for data relating to R&D projects and technological resources in the fields of MIE and AMR.

The data and expertise provided by the IHU Méditerranée Infection will enrich this platform, thereby enhancing the visibility of projects, mapping skills, and identifying high-impact opportunities for collaboration.

A shared vision for public health

IHU Méditerranée Infection is an international center of excellence dedicated to research, care, and innovation in emerging infectious diseases and antibiotic resistance, backed by high-level technological platforms and strong university hospital expertise.

IDCluster, France 2030 national biocluster, is a national collaborative organization that accelerates innovation and industrial development in these same fields by bringing together a broad ecosystem of public and private players.

By joining forces, the two partners aim to strengthen the continuum between research, innovation, and public health impact, and to promote the emergence of public-private projects in order to respond more effectively to the growing challenges posed by emerging infectious diseases and antimicrobial resistance.

ANRS Emerging Infectious Diseases (ANRS MIE) and the Infectious Diseases Cluster (IDCluster) have signed an agreement formalizing the launch of a joint initiative to explore the feasibility of a scientific and economic intelligence platform dedicated to infectious diseases (the ID360 platform).

In a context marked by increasing threats related to emerging infectious diseases (EIDs) and antimicrobial resistance (AMR), this initiative responds to the need to strengthen anticipation capacities and improve coordination among scientific, industrial, and institutional stakeholders.

The ambition of the ID360 platform is to:

• Dynamically map research and innovation projects;
• Identify available expertise, infrastructures, and capacities;
• Facilitate interactions between academic, clinical, industrial, and institutional stakeholders;
• Support strategic reflection and decision-making for public and private actors.

An initial exploratory phase is currently underway, including international benchmarking, the development of functional and technical specifications, and a feasibility assessment.

This public–private partnership comes at a time of strengthened national and European strategies for preparedness and response to health crises.

It builds on the complementarity between the two partners:

• ANRS MIE contributes its scientific expertise, its deep understanding of the academic and institutional ecosystem, and its structuring role at the national level.
• IDCluster drives the innovation ecosystem in the fields of EIDs and AMR through close interaction with economic and clinical stakeholders.

Within a two-year horizon, the ambition is clear: to equip France with a structuring tool capable of accelerating high-impact innovative solutions in public health and sustainably strengthening our ability to anticipate future health crises. In the longer term, this tool could also be extended to other countries within the European Union.